Skip to main content
CivicGate

HR 10359
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Priority for Pediatric Cures Act

To amend the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products.

Introduced Sep 14, 2026

Latest action (Sep 14, 2026) Referred to the House Committee on Energy and Commerce.

Referred to
Energy and Commerce Committee

Sponsor (1)
5 cosponsors

Money behind the sponsor

Top reported contributors to Gus M. Bilirakis’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • Employer not reported $24,400
  • LINCARE $11,000
  • HOLLAND & KNIGHT $7,600
  • MCI $6,600
  • S&S $6,600

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Gus M. Bilirakis → · Outside spending →

Actions (2)
  1. Sep 14, 2026 Referred to the House Committee on Energy and Commerce. · house
  2. Sep 14, 2026 Introduced in House

Text versions (1)
  • Introduced in House · Sep 14, 2026

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE HOUSE OF REPRESENTATIVES

September 14, 2026

Mr. Bilirakis (for himself, Ms. Barragan, Mrs. Cammack, Mr. Auchincloss, Mr. Kean, and Mr. Mullin) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Priority for Pediatric Cures Act”.

SEC. 2. PERMANENT EXTENSION OF AUTHORITY TO AWARD PRIORITY REVIEW VOUCHERS FOR RARE PEDIATRIC DISEASE PRODUCTS.

Section 529(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)) is amended by striking paragraph (5). <all>

Comments

Comments

Loading comments…